YAbS







Pagibaximab Terminated Naked monospecific

Antibody Information

Entry ID 1958
INN Pagibaximab
Status Terminated
Drug code(s) BSYX-A110, hu96-110
Brand name None
mAb sequence source mAb chimeric
General Molecular Category Naked monospecific
Format, general category Full length Ab
Format details None
Isotype (Fc) IgG1
Light chain isotype kappa
Linker None
Ave. DAR None
Conjugated/fused moiety None
Discovery method/technology None

Therapeutic information

Target(s) Staphylococcal lipoteichoic acid
Indications of clinical studies Staphylococcal Sepsis in very low birth weight neonates
Primary therapeutic area Infectious diseases

Development stage information

Phase lengths*
*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).
Most advanced stage of development (global) Terminated at Phase 2/3
Status Inactive
Start of clinical phase (IND filing or first Phase 1) July 02, 2001
Start of Phase 2 March 15, 2003
Start of Phase 3
Date BLA/NDA submitted to FDA
Year of first approval (global) None
Date of first US approval
INN, US product name None
US or EU approved indications None

Company information

Company Sunol Molecular
Licensee/Partner Biosynexus Incorporated, GSK
Comments about company or candidate None
Full address of company 2810 N COMMERCE PKY, MIRAMAR, FL 33025, United States
North America
United States of America
https://www.sbir.gov/node/320095

Description/comment

Target is “Staphylococcal lipoteichoic acid” according to https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704668/

Additional information

Anticipated events None
Factor(s) contributing to discontinuation None